Anticancer activity, toxicity and pharmacokinetic profile of an indanone derivative

Add time:09/09/2019    Source:sciencedirect.com

The present study describes anticancer effect of gallic acid based indanone derivative (1). Indanone 1 exhibited in vivo anticancer activity against Erhlich ascites carcinoma in Swiss albino mice by inhibiting tumor growth by 54.3% at 50 mg/kg b.wt. It showed antitubulin effect by inhibiting tubulin polymerase enzyme. In cell cycle analysis, it inhibited G2/M phase and induced apoptosis. It significantly suppressed VEGF-R1, VEGF-R2 and HIF-α in human breast cancer MCF-7 cells, thus exhibiting antiangiogenic activity. In acute oral toxicity, indanone 1 was well tolerated and was found to be non-toxic up to 1000 mg/kg b.wt. in Swiss albino mice. Pharmacokinetic studies in rabbits revealed rate of absorption, half life, volume of distribution with high plasma and blood clearance after i.v. administration. Indanone 1, is a safe and moderately active anticancer agent.

We also recommend Trading Suppliers and Manufacturers of 4,5,6-TRIMETHOXY-INDANONE (cas 16718-42-6). Pls Click Website Link as below: cas 16718-42-6 suppliers

Prev:Electronic tuning cyclization of aryl-1,4-enediones: AlCl3-mediated Nazarov-type cyclization to synthesize polysubstituted-1-indanones
Next:Effects of sodium metavanadate on in vitro neuroblastoma and red blood cells)